3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Breast Neoplasms
2
Solid Tumours
1
Side-effect of Antibiotic
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Long QT Syndrome
1
Hot Flashes
1
Hodgkin Disease
1
Carcinoma, Renal Cell
1
Bacteremia
1
Advanced Breast Cancer
1
Interventions
Dexamethasone
363
Bortezomib
232
Lenalidomide
202
Cyclophosphamide
174
Melphalan
154
Calcium Dobesilate
107
Peripheral Blood Stem Cell Transplantation
92
fludarabine phosphate
84
Thalidomide
81
Filgrastim
71
carfilzomib
68
pomalidomide
66
Granulocyte Colony-Stimulating Factor
60
Mycophenolic Acid
59
Busulfan
57
daratumumab
55
Whole-Body Irradiation
54
Tacrolimus
51
ixazomib
50
Prednisone
50
Cyclosporine
49
fludarabine
46
Antilymphocyte Serum
35
Etoposide
30
dexamethasone acetate
29
Methotrexate
29
plerixafor
27
Radiotherapy
26
Doxorubicin
26
dexamethasone 21-phosphate
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Multiple Myeloma
×
Moxifloxacin
×
Clear all
NCT00398411
2015-06-29
MoxiProph
University of Cologne
Phase 3
Completed
66 enrolled
15 charts